Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder

被引:16
|
作者
Belgaied, Wael [1 ]
Sarnp, Jennifer [2 ]
Vimont, Alexandre [1 ]
Remuzat, Cecile [1 ]
Aballea, Samuel [1 ]
El Hammi, Emna [1 ]
Kooli, Amna [1 ]
Toumi, Mondher [1 ,3 ]
Akhras, Kasem [2 ]
机构
[1] Creativ Ceutical, Deerfield, IL USA
[2] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[3] Univ Lyon 1, UFR Odontol, F-69372 Lyon, France
关键词
Cognitive dysfunction; Schizophrenia; Major depressive disorder; Bipolar disorder; Cognitive instruments; Survey; NEUROCOGNITIVE IMPAIRMENT; BATTERY;
D O I
10.1016/j.euroneuro.2013.11.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As more evidence points to the association of cognitive dysfunction with mental health disorders, the assessment of cognitive function in routine clinical care of these disorders is increasingly important. Despite this, it remains unknown how cognitive function is measured in routine clinical practice. The objective of this study was to assess psychiatrists awareness of cognitive dysfunction in mental health disorders and their methods of cognitive assessment. An online survey was disseminated to psychiatrists in Europe, Asia, Australia and the United States. The survey asked about their perceptions of cognitive dysfunction in several mental health disorders, knowledge of cognitive assessment, method of cognitive assessment, and instruments used to measure cognitive function. Among the 61 respondents, most perceived that schizophrenia was associated with the greatest cognitive dysfunction. Many were unaware whether guidelines were available on cognitive assessment. In schizophrenia, 59% of psychiatrists reportedly used cognitive instruments, while the remainder relied solely on patient history interviews. The use of instruments to assess cognition in major depressive disorder (MDD) and bipolar disorder (BPD) was lower, 38% and 37% respectively. Of the reported instruments used, only a few were actually appropriate for use in the diseases of interest (12% in schizophrenia, 3% in MDD and 0% in BPD). Other instruments reported were clinical measures that did not assess cognition. These findings reveal some inconsistencies in psychiatrists' routine clinical evaluation of cognitive function. There appeared to be low use of true cognitive assessment instruments in clinical practice and confusion regarding what constituted a cognitive assessment instrument. (C) 2013 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [41] Comparison of depressive episodes in bipolar disorder and in major depressive disorder within bipolar disorder pedigrees
    Mitchell, Philip B.
    Frankland, Andrew
    Hadzi-Pavlovic, Dusan
    Roberts, Gloria
    Corry, Justine
    Wright, Adam
    Loo, Colleen K.
    Breakspear, Michael
    BRITISH JOURNAL OF PSYCHIATRY, 2011, 199 (04) : 303 - 309
  • [42] Ionotropic glutamate receptor expression in the brain in schizophrenia bipolar disorder, and major depressive disorder
    Meador-Woodruff, JH
    Hogg, AJ
    Agrawal, S
    Smith, RE
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 54 - 54
  • [43] The role of tumour necrosis factor in the pathophysiology of major depressive disorder, bipolar disorder and schizophrenia
    Gibbons, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 40 - 40
  • [44] Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia
    Canali, Paola
    Sarasso, Simone
    Rosanova, Mario
    Casarotto, Silvia
    Sferrazza-Papa, Giovanna
    Gosseries, Olivia
    Fecchio, Matteo
    Massimini, Marcello
    Mariotti, Maurizio
    Cavallaro, Roberto
    Smeraldi, Enrico
    Colombo, Cristina
    Benedetti, Francesco
    JOURNAL OF AFFECTIVE DISORDERS, 2015, 184 : 111 - 115
  • [45] Temporal changes of gene expression in health, schizophrenia, bipolar disorder, and major depressive disorder
    Arakelyan, Arsen
    Avagyan, Susanna
    Kurnosov, Aleksey
    Mkrtchyan, Tigran
    Mkrtchyan, Gohar
    Zakharyan, Roksana
    Mayilyan, Karine R.
    Binder, Hans
    SCHIZOPHRENIA, 2024, 10 (01)
  • [46] Impact of Antipsychotic Treatment Switching in Patients With Schizophrenia, Bipolar Disorder, And Major Depressive Disorder
    Carroll, Benjamin
    Ayyagari, Rajeev
    Thomason, Darren
    Mu, Fan
    Philbin, Michael
    NEUROLOGY, 2019, 92 (15)
  • [47] Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder
    Meador-Woodruff, JH
    Hogg, AJ
    Smith, RE
    BRAIN RESEARCH BULLETIN, 2001, 55 (05) : 631 - 640
  • [48] BDgene: A Genetic Database for Bipolar Disorder and Its Overlap With Schizophrenia and Major Depressive Disorder
    Chang, Su-Hua
    Gao, Lei
    Li, Zhao
    Zhang, Wei-Na
    Du, Yang
    Wang, Jing
    BIOLOGICAL PSYCHIATRY, 2013, 74 (10) : 727 - 733
  • [49] Emotion-Behavior Decoupling in Individuals With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
    Wang, Yan-yu
    Ge, Mao-hong
    Zhu, Guo-hui
    Jiang, Neng-zhi
    Wang, Gui-zhen
    Lv, Shi-xin
    Zhang, Qin
    Guo, Jian-nan
    Tian, Xue
    Lui, Simon S. Y.
    Cheung, Eric F. C.
    Heerey, Erin A.
    Sun, Hong-wei
    Chan, Raymond C. K.
    JOURNAL OF ABNORMAL PSYCHOLOGY, 2020, 129 (04) : 331 - 342
  • [50] Reduced oscillatorynatural frequencies of the frontal cortex in schizophrenia, bipolar disorder and major depressive disorder
    Benedetti, F.
    Canali, P.
    Papa, G. Sferrazza
    Smeraldi, E.
    Colombo, C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 72 - 72